PolysacDB Capsular polysaccharide 2422
From DrugPedia: A Wikipedia for Drug discovery
m (1 revision) |
m (1 revision) |
Current revision
[edit] Carbohydrate Name
Capsular polysaccharide
[edit] Carbohydrate Class
Capsular polysaccharide
[edit] Source Microbe
Streptococcus Group B
[edit] Basic Structure
The structure of type III polysaccharide is as follows : -3-β-D-Galp-(1-->4)-β-D-Glcp-(1-->6)-β-D-GlcNAcp-(1--> along with the fact that the carboxyl of the -D-NeuNAcp was linked to the O-3 of the adjacent D-galactose to form the type-specific site
[edit] Proposed functions
The property of invasiveness is related to the anti-phagocytic properties conferred to Group B Streptococcus by its capsular polysaccharide
[edit] Antigenic Nature used to produce antibodies
Glycoconjugates
[edit] Carrier Name
Tetanus toxoid
[edit] Conjugation Method
Type III polysaccharide was activated with cyanogen bromide at pH 10.5 for 6 min at 4C. Adipic acid dihydrazide was added in 0.5 M NaHCO3 to a final concentration of 0.25 M, pH 8.5. the reaction mixture was dialyzed against 0.2 M NaCl at 3 to 8C and passed through a 4B-CL Sepharose column. The CP-containing fractions were pooled, dialyzed against sterile pyrogen-free water, and freeze-dried. A solution containing 10 mg each of type III-AH and TT per ml was brought to pH 5.6 with 0.1 N HCl. 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide was added to a final concentration of 0.05 M. The reaction mixture was dialyzed against 0.2 M NaCl at 3 to 8C and was passed through a 4B-CL Sepharose column
[edit] Antibodies
Antisera
[edit] Antibody type and class
IgG
[edit] Assay System
Double immunodiffusion and capillary precipitation, opsonization assays
[edit] Cross-reactivity
This antisera was quite specific and did not react with the structurally related pneumococcus type 14 polysaccharide
[edit] Proposed epitopes
N/A
[edit] Proposed Utility
Conjugate-induced antibodies facilitated opsonization of group B streptococcus type III organisms. The type III-TT conjugate can be a potential vaccine for prevention of neonatal Group B Streptococcal diseases.
